Education
About Us
Working with TipRanks
Follow Us
ONO Pharmaceutical Co Ltd (OPHLF)
OTHER OTC:OPHLF
Total Valuation
ONO Pharmaceutical Co has a market cap or net worth of $6.60B. The enterprise value is $736.21B.
Market Cap$6.60B
Enterprise Value$736.21B
Share Statistics
ONO Pharmaceutical Co has 498,692,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding498,692,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ONO Pharmaceutical Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.32%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.32%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee126.36M
Profits Per Employee15.40M
Employee Count3,853
Asset Turnover0.46
Inventory Turnover1.98
Valuation Ratios
The current PE Ratio of ONO Pharmaceutical Co is 18.9. ONO Pharmaceutical Co’s PEG ratio is -0.25.
PE Ratio18.9
PS Ratio1.55
PB Ratio0.96
Price to Fair Value0.96
Price to FCF10.12
Price to Operating Cash Flow10.00
PEG Ratio-0.25
Income Statement
In the last 12 months, ONO Pharmaceutical Co had revenue of 486.87B and earned 50.05B in profits. Earnings per share was 106.55.
Revenue486.87B
Gross Profit338.92B
Operating Income59.75B
Pretax Income59.33B
Net Income50.05B
EBITDA91.54B
Earnings Per Share (EPS)106.55
Cash Flow
In the last 12 months, operating cash flow was 102.30B and capital expenditures -6.54B, giving a free cash flow of 95.77B billion.
Operating Cash Flow102.30B
Free Cash Flow95.77B
Free Cash Flow per Share192.03
Dividends & Yields
ONO Pharmaceutical Co pays an annual dividend of $0.257, resulting in a dividend yield of 4.04%
Dividend Per Share$0.257
Dividend Yield4.04%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change28.19%
50-Day Moving Average12.03
200-Day Moving Average11.02
Relative Strength Index (RSI)77.46
Average Volume (3m)1.67K
Important Dates
ONO Pharmaceutical Co upcoming earnings date is Feb 2, 2026, TBA (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateFeb 2, 2026
Ex-Dividend Date―
Financial Position
ONO Pharmaceutical Co as a current ratio of 3.07, with Debt / Equity ratio of 16.17%
Current Ratio3.07
Quick Ratio2.56
Debt to Market Cap0.18
Net Debt to EBITDA-0.63
Interest Coverage Ratio11.23
Taxes
In the past 12 months, ONO Pharmaceutical Co has paid 9.16B in taxes.
Income Tax9.16B
Effective Tax Rate0.15
Enterprise Valuation
ONO Pharmaceutical Co EV to EBITDA ratio is 7.60, with an EV/FCF ratio of 9.34.
EV to Sales1.43
EV to EBITDA7.60
EV to Free Cash Flow9.34
EV to Operating Cash Flow8.44
Balance Sheet
ONO Pharmaceutical Co has $182.93B in cash and marketable securities with $130.41B in debt, giving a net cash position of $52.51B billion.
Cash & Marketable Securities$182.93B
Total Debt$130.41B
Net Cash$52.51B
Net Cash Per Share$105.30
Tangible Book Value Per Share$929.10
Margins
Gross margin is 67.63%, with operating margin of 12.27%, and net profit margin of 10.28%.
Gross Margin67.63%
Operating Margin12.27%
Pretax Margin12.19%
Net Profit Margin10.28%
EBITDA Margin18.80%
EBIT Margin13.28%
Analyst Forecast
The average price target for ONO Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―